TAT fusion proteins against ischemic stroke: Current status and future perspectives

Frontiers in Bioscience

Volumn 11, Issue 2 P.1591-2006, 2006, Pages 1716-1721

  Kilic, Ertugrul ^a   Kilic, Ulkan ^a   Hermann, Dirk M ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Apoptosis; Bcl Xl; Brain; Cell death; Cytokine; Focal cerebral ischemia; GDNF; HIV TAT protein; Nervous system; Neuroprotection; Review

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 32844462839     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/1917     Document Type: Review

References (56)

1. Yuan J, M. Lipinski, & A. Degterev: Diversity in the mechanisms of neuronal cell death. Neuron. 2003;40(2):401-13.
2. Isenmann S, C. Schmeer & A. Kretz: How to keep injured CNS neurons viable-strategies for neuroprotection and gene transfer to retinal ganglion cells. Mol Cell Neurosci 26, 1-16 (2004)
3. Benn S.C. & C.J. Woolf: Adult neuron survival strategies - slamming on the brakes. Nat Rev Neurosci 5, 686-700 (2004)
4. Dietz G.P, E. Kilic & M. Bähr: Inhibition of neuronal apoptosis in vitro and in vivo using TAT-mediated protein transduction. Mol Cell Neurosci 21, 29-37 (2002)
5. Kilic E, G.P. Dietz, D.M. Hermann & Bähr M: Intravenous TAT-Bcl-XI is protective after middle cerebral artery occlusion in mice. Ann Neurol 52, 617-622 (2002)
6. Lum H. & A.B. Malik: Mechanisms of increased endothelial permeability. Can J Physiol Pharmacol 74, 787-800 (1996)
7. Wolburg H, & A. Lippoldt: Tight junctions of the blood-brain barrier: development, composition and regulation. Vascul Pharmacol 38, 323-337 (2002)
8. Huber J.D, R.D. Egleton & T.P. Davis: Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier. Trends Neurosci 24, 719-725 (2001)
9. Stewart P.A: Endothelial vesicles in the blood-brain barrier: are they related to permeability? Cell Mol Neurobiol 20, 149-163 (2000)
10. Rippe B, B.I. Rosengren, O. Carlsson & D. Venturoli: Transendothelial transport: the vesicle controversy. J Vasc Res 39, 375-390 (2002)
11. Cipolla M.J, R. Crete, L. Vitullo & R.D. Rix: Transcellular transport as a mechanism of blood-brain barrier disruption during stroke. Front Biosci 9, 777-785 (2004)
12. Tsukamoto T. & S.K. Nigam: Tight junction proteins form large complexes and associate with the cytoskeleton in an ATP depletion model for reversible junction assembly. J Biol Chem 272, 16133-16139 (1997)
13. Kondo T, H. Kinouchi, M. Kawase & T. Yoshimoto: Astroglial cells inhibit the increasing permeability of brain endothelial cell monolayer following hypoxia/reoxygenation. Neurosci Lett 208, 101-104 (1996)
14. Yamagata K, M. Tagami, Y. Nara, H. Fujino, A. Kubota, F. Numano, T. Kato & Y. Yamori: Faulty induction of blood-brain barrier functions by astrocytes isolated from stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 24, 686-691 (1997)
15. Latour L.L, D.W. Rang, M.A. Ezzeddine, J.A. Chalela & S. Warach: Early blood-brain barrier disruption in human focal brain ischemia. Ann Neurol 56, 468-477 (2004)
16. Kitagawa H, C. Sasaki, K. Sakai, A. Mori, Y. Mitsumoto, T. Mori, Y. Fukuchi, Y. Setoguchi & Abe K: Adenovirus-mediated gene transfer of glial cell line-derived neurotrophic factor prevents ischemic brain injury after transient middle cerebral artery occlusion in rats. J Cereb Blood Flow Metab 19, 1336-1344 (1999)
17. Hermann D.M, E. Kilic, S. Kügler, S. Isenmann & Bähr M: Adenovirus-mediated GDNF and CNTF pretreatment protects against striatal injury following transient middle cerebral artery occlusion in mice. Neurobiol Dis 8, 655-666 (2001)
18. Hermann DM, E. Kilic, S. Kügler, S. Isenmann & Bähr M: Adenovirus-mediated glial cell line-derived neurotrophic factor (GDNF) expression protects against subsequent cortical cold injury in rats. Neurobiol Dis 8, 964-973 (2001)
19. Kilic E, D.M. Hermann, S. Kügler, U. Kilic, H. Holzmüller, C. Schmeer & M. Bähr: Adenovirus-mediated Bcl-X(L) expression using a neuron-specific synapsin-1 promoter protects against disseminated neuronal injury and brain infarction following focal cerebral ischemia in mice. Neurobiol Dis 11, 275-284 (2002)
20. Byrnes A.P, R.E. MacLaren & H.M. Charlton: Immunological instability of persistent adenovirus vectors in the brain: peripheral exposure to vector leads to renewed inflammation, reduced gene expression, and demyelination. J Neurosci 16, 3045-3055 (1996)
21. Lowenstein P.R & M.G. Castro: Inflammation and adaptive immune responses to adenoviral vectors injected into the brain: peculiarities, mechanisms, and consequences. Gene Ther 10, 946-954 (2003)
22. Kochanek S, G. Schiedner & C. Volpers: High-capacity 'gutless' adenoviral vectors. Curr Opin Mol Ther 3, 454-463 (2001)
23. Eslamboli A, B. Georgievska, R.M. Ridley, H.F. Baker, N. Muzyczka, C. Burger, R.J. Mandel, L. Annett & D. Kirik: Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease. J Neurosci 25, 769-777 (2005)
24. Blomer U, A. Ganser & M. Scherr: Invasive drug delivery. Adv Exp Med Biol 513, 431-451 (2002)
25. Begley DJ: Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Ther 104, 29-45 (2004)
26. Hossmann K.A: Disturbances of cerebral protein synthesis and ischemic cell death. Prog Brain Res 96, 161-177 (1993)
27. Hermann D.M, E. Kilic, R. Hata, K.A. Hossmann & G. Mies: Relationship between metabolic dysfunctions, gene responses and delayed cell death after mild focal cerebral ischemia in mice. Neuroscience 104, 947-955 (2001)
28. Hata R, K. Maeda, D. Hermann, G. Mies & K.A. Hossmann: Evolution of brain infarction after transient focal cerebral ischemia in mice. J Cereb Blood Flow Metab 20, 937-946 (2000)
29. Althausen S, T. Mengesdorf, G. Mies, L. Olah, A.C. Nairn, C.G. Proud & W. Paschen: Changes in the phosphorylation of initiation factor eIF-2alpha, elongation factor eEF-2 and p70 S6 kinase after transient focal cerebral ischaemia in mice. J Neurochem 78, 779-787 (2001)
30. Zhang W.R, K. Sato, M. Iwai, I. Nagano, Y. Manabe & K. Abe: Therapeutic time window of adenovirus-mediated GDNF gene transfer after transient middle cerebral artery occlusion in rat. Brain Res 947, 140-145 (2002)
31. Frankel A. D. & C.O. Pabo: Cellular uptake of the Tat protein from human immunodeficiency virus. Cell 55, 1189-1193 (1988)
32. Green M. & P.M. Loewenstein: Autonomous functional domains of chemically synthesized human immunodeficiency virus Tat trans-activator protein. Cell 55, 1179-1188 (1988)
33. Fawell S, J. Seery, Y. Daikh, C. Moore, L.L. Chen, B. Pepinsky & J. Barsoum: Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci USA 91, 664-668 (1994)
34. Schwarze S.R, A. Ho, B.A. Vocero-Akban & S.F. Dowdy: In vivo protein transduction: Delivery of a biologically active protein into the mouse. Science 285, 1569-1572 (1999)
35. Ho A, S.R. Schwarze, S.J. Mermelstein, G. Waksman & S.F. Dowdy: Synthetic protein transduction domains: enhanced transduction potential in vitro and in vivo. Cancer Res 61, 474-477 (2001)
36. Sandgren S, F. Cheng & M. Belting: Nuclear targeting of macromolecular polyanions by an HIV-Tat derived peptide. Role for cell-surface proteoglycans. J Biol Chem 277, 38877-38883 (2002)
37. Fittipaldi A, A. Ferrari, M. Zoppe, C. Arcangeli, V. Pellegrini, F. Beltram & M. Giacca: Cell membrane lipid rafts mediate caveolar endocytosis of HIV-1 Tat fusion proteins. J Biol Chem 278, 34141-34149 (2003)
38. Kaplan I.M, J.S. Wadia & S.F. Dowdy: Cationic TAT peptide transduction domain enters cells by macropinocytosis. J Control Release 102, 247-253 (2005)
39. Nagahara H, A.M. Vocero-Akbani, E.L. Snyder, A. Ho, D.G. Latham, N. A. Lissy, M. Becker-Hapak, S.A. Ezhevsky & S.F. Dowdy: Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. Nat Med 4, 1449-1452 (1998)
40. Schwarze S.R, K.A. Hruska & S.F. Dowdy: Protein transduction: unrestricted delivery into all cells? Trends Cell Biol 10, 290-295 (2000)
41. Prochiantz A: Homeodomain-derived peptides. In and out of the cells. Ann N Y Acad Sci 886, 172-179 (1999)
42. Joliot A. & A. Prochiantz: Transduction peptides: from technology to physiology. Nat Cell Biol 6, 189-196. (2004)
43. Love S: Apoptosis and brain ischaemia. Prog Neuropsychopharmacol Biol Psychiatry 27, 267-282 (2003)
44. Ferrer I. & A.M. Planas: Signaling of cell death and cell survival following focal cerebral ischemia: life and death struggle in the penumbra. J Neuropathol Exp Neurol 62, 329-339 (2003)
45. Plesnila N: Role of mitochondrial proteins for neuronal cell death after focal cerebral ischemia. Acta Neurochir Suppl 89, 15-19 (2004)
46. Green D.R. & G. Kroemer: The pathophysiology of mitochondrial cell death. Science 305, 626-629 (2004)
47. Kilic Ü, E. Kilic, G.P. Dietz & M. Bahr: Intravenous TAT-GDNF is protective after focal cerebral ischemia in mice. Stroke 34, 1304-1310 (2003)
48. Cao G, W. Pei, H. Ge, Q. Liang, Y. Luo, F.R. Sharp, A. Lu, R. Ran, S.H. Graham & J. Chen: In vivo Delivery of a Bcl-xL Fusion Protein Containing the TAT Protein Transduction Domain Protects against Ischemic Brain Injury and Neuronal Apoptosis. J Neurosci 22, 5423-5431 (2002)
49. Asoh S, I. Ohsawa, T. Mori, K. Katsura, T. Hiraide, V. Katayama, M. Kimura, D. Ozaki, K. Yamagata & S. Ohta: Protection against ischemic brain injury by protein therapeutics. Proc Nail Acad Sci U S A 99, 17107-17112 (2002)
50. Borsello T, P.G. Clarke, L. Hirt, A. Vercelli, M. Repici, D.F. Schorderet, J. Bogousslavsky & C. Bonny: A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. Nat Med 9, 1180-6 (2003)
51. Kim D.W, W.S. Bum, S.H. Jang, S.Y. Kim, H.S. Choi, S.H. Choi, J.J. An, S.H. Lee, K.S. Lee, K. Han, T.C. Kang, M.H. Won, J.H. Kang, O.S. Kwon, S.W. Cho, T.Y. Kim, J. Park & S.Y. Choi: Transduced Tat-SOD Fusion Protein Protects Against Ischemic Brain Injury. Mol Cells 19, 88-96 (2005)
52. Dietz G.P. & M. Bahr: Delivery of bioactive molecules into the cell: the Trojan horse approach. Mol Cell Neurosci 27, 85-131 (2004)
53. Falnes P.O, J. Wesche & S. Olsnes: Ability of the Tat basic domain and VP22 to mediate cell binding, but not membrane translocation of the diphtheria toxin A-fragment. Biochemistry 40, 4349-4358 (2001)
54. Corradin S, A. Ransijn, G. Corradin, J. Bouvier, M.B. Delgado, J. Fernandez-Carneado, J.C. Mottram, G. Vergeres & J. Mauel: Novel peptide inhibitors of Leishmania gp63 based on the cleavage site of MARCKS (myristoylated alanine-rich C kinase substrate)-related protein. Biochem J 367, 761-9 (2002)
55. Krämer S.D. & H. Wunderli-Allenspach H. No entry for TAT(44-57) into liposomes and intact MDCK cells: novel approach to study membrane permeation of cell-penetrating peptides. Biochim Biophys Acta 1609, 161-9 (2003)
56. Sengoku T, V. Bondada, D. Hassane, S. Dubal & J.W. Geddes: Tat-calpastatin fusion proteins transduce primary rat cortical neurons but do not inhibit cellular calpain activity. Exp Neurol 188, 161-70 (2004)